EGFR and non-small cell lung carcinoma: In contrary, a phase I/II single arm study reported by Yu et al. showcased a positive result in which osimertinib plus bevacizumab in treatment-naïve EGFR-mutant NSCLC patients met the pre-specified effectiveness end point19.